Patients with type 2 diabetes treated with sodium-glucose cotransporter-2 (SGLT-2) inhibitors have a significantly lower risk of developing dementia and Alzheimer's disease than those receiving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results